Enzon Pharmaceuticals News

Enzon Pharmaceuticals, Inc. announced today that it has set Wednesday, January 27, 2010 as the date of the special meeting of stockholders to vote on the proposed sale of its specialty pharmaceutical business to the sigma-tau Group.

Enzon Pharmaceuticals Inc. said Tuesday it will hold a shareholder meeting on Jan.

In an amended 13G just filed with the SEC, Seth Klarman's hedge fund Baupost Group has disclosed a 5.45% ownership stake in Syneron Medical .

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Under the terms of the agreement, 3M provides its TLR agonists to VaxInnate for an undisclosed licensing fee, in addition to milestone and royalty payments.

Investment Guru Seth Klarman has been busy buying distressed debt nowadays and he might just ignored stocks.

Enzon achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent.

Seth Klarman's well known hedge fund Baupost Group recently filed two separate 13G's with the SEC in which it updated positions.

U.S. Sen. Jay Rockefeller says current federal energy legislation doesn't do enough to protect West Virginia's coal industry.

Enzon Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/03/09, EpiCept Corporation announced a Nasdaq Hearings Panel has granted the Companys request for continued listing on The Nasdaq Stock Market.

Enzon Inc. filed Quarterly Report for the period ended 2009-09-30. Enzon Pharmaceuticals Inc.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 10/28/09, Arrayit Corporation announced the sale of a system to the Center of Excellence for Nucleic Acid-Based Technologies in Poznan, Poland.

Here is a list of 15 stocks which traded higher Wednesday on unusually higher volume.

Main Category: Arthritis / Rheumatology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 08 Oct 2009 Enzon Pharmaceuticals, Inc.

Main Category: Melanoma / Skin Cancer Also Included In: Regulatory Affairs / Drug Approvals Article Date: 06 Oct 2009 Enzon Pharmaceuticals, Inc.

ENGLEWOOD, Colo.-- --The Western Union Company , lider en la industria de las transferencias de dinero a escala mundial, ha comunicado que la Presidenta y Consejera delega... 10/05/2009 - 02:45 PM ST.

Analyst Report ) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria .

Danish firm Santaris Pharma AS racked up another multimillion dollar deal to develop drugs based on its locked nucleic acid platform targeting microRNAs and messenger RNAs, this time with London-based Shire plc for drugs to treat rare genetic disorders.

Danish firm Santaris Pharma AS racked up another multimillion dollar deal to develop drugs based on its locked nucleic acid platform targeting microRNAs and messenger RNAs, this time with London-based Shire plc for drugs to treat rare genetic disorders.